Guidance, NICE advice and quality standards in development | Guidance

Showing 231 to 240 of 375

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Optical Coherence Tomography to guide percutaneous coronary intervention	Interventional procedures guidance	TBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]	Technology appraisal guidance	TBC
Orforglipron for managing overweight and obesity [ID6516]	Technology appraisal guidance	18 November 2026
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]	Technology appraisal guidance	29 April 2026
Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer [ID6472]	Technology appraisal guidance	TBC
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)	NICE guideline	15 July 2026
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]	Technology appraisal guidance	TBC
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]	Technology appraisal guidance	TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]	Technology appraisal guidance	TBC
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]	Technology appraisal guidance	23 July 2026